

In the Claims:

Please amend claim 1 as follows:

B²
1. (Currently Amended) A method of treating gastroduodenal disease in a mammal, said method comprising administering a therapeutically effective amount of a composition comprising a substantially purified Helicobacter urease peptide to said mammal [peptides].

2. (Original) The method of claim 1 wherein said gastroduodenal disease is gastritis.

3. (Original) The method of claim 1 wherein said gastroduodenal disease is peptic ulcer disease.

4. (Original) The method of claim 1 wherein said gastroduodenal disease is chronic dyspepsia with severe erosive gastroduodenitis.

5. (Original) The method of claim 1 wherein said gastroduodenal disease is refractory non-ulcer dyspepsia.

6. (Original) The method of claim 1 wherein said gastroduodenal disease is intestinal metaplasia.

7. (Original) The method of claim 1 wherein said gastroduodenal disease is low grade MALT lymphoma.

8. (Original) The method of claim 1 wherein said gastroduodenal disease is Helicobacter infection.

9. (Original) The method of claim 1 wherein said gastroduodenal disease is Helicobacter pylori infection.

10. (Original) The method of claim 1 wherein said gastroduodenal disease is H. felis disease.

11. (Original) The method of claim 1 wherein said mammal is human.

12. (Original) The method of claim 1 wherein said composition comprises Helicobacter urease.

13. (Original) The method of claim 1 wherein said composition comprises the ure B subunit of Helicobacter urease.

14. (Original) The method of claim 1 wherein said composition comprises the ure B subunit of Helicobacter pylori urease.

15. (Original) The method of claim 1 further comprising administering said composition

to a mucosal surface.

16. (Original) The method of claim 1 wherein said composition is administered orally, nasally, rectally, or ocularly.

17. (Original) The method of claim 1 further comprising administering said composition in a dosage ranging from 100 μ g to 1 g.

B3
18. (Original) The method of claim 17 further comprising administering said dosage over three to eight doses for a primary immunization schedule over one month.

19. (Original) The method of claim 1 wherein said composition is administered in association with a mucosal adjuvant.

20-88. (Canceled).
